Home/Pipeline/M8891

M8891

Advanced Solid Tumors

Phase 1/2Active

Key Facts

Indication

Advanced Solid Tumors

Phase

Phase 1/2

Status

Active

Company

Merck KGaA

About Merck KGaA

Merck KGaA's mission is to advance science and technology to improve lives and solve pressing challenges. Its key achievements include building a leading oncology franchise with Bavencio, establishing MilliporeSigma as a dominant global supplier to the life science industry, and becoming a critical materials partner for the electronics sector. The company's strategy leverages its deep scientific expertise across its three interconnected pillars to capitalize on long-term trends in healthcare digitization, biopharma outsourcing, and technological miniaturization.

View full company profile

Therapeutic Areas

Oncology Neurology Immunology

Other Advanced Solid Tumors Drugs

Drug	Company	Phase	Status
NT219	Purple Biotech	Phase 1/2	Active
INDP-101	Indaptus Therapeutics	Phase 1	Active, not recruiting
PM14	PharmaMar	Phase 1/2	Active
Ecubectedin (PM54)	PharmaMar	Phase 1	Active
AP-202	Advance Pharmaceutical	Phase 1/2	Active, dose expansion
BP1001-A	Bio-Path Holdings	Phase 1	Active
FS222	F-star Therapeutics	Phase 1	Active (status post-acquisition)
FS120	F-star Therapeutics	Phase 1	Active (status post-acquisition)
GIGA-564	GigaGen	Phase 1	Active
Venadaparib (IDX-1197)	Idience	Phase 1a	Completed
VET3-TGI	KaliVir Immunotherapeutics	Phase 1	Active
IT-141 (Etoposide IVECT™)	Intezyne	Phase 1	Active